Drug recall · October 24, 2018
Temozolomide capsules recall
Why: Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071.
- Lots / codes
Lot #: a) 17F058A, Exp 6/19; b) 17F058B, Exp 6/19
- Quantity
- 5,232 bottles: a) 4,146 bottles; b) 1,086 bottles
- Company
- Amerigen Pharmaceuticals Inc., Lyndhurst, NJ
- Distribution
- Product was distributed U.S. nationwide.
- Initiated
- October 5, 2018 · Voluntary: Firm initiated
- Classified
- November 15, 2018
- Reported
- October 24, 2018
- Ended
- September 30, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Temozolomide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.